Our internal discovery focuses on Hemostasis and Thrombotic diseases driven by a number of reasons:
- Significant scientific knowledge and domain expertise.
- Existing therapies are lacking.
standard drugs available in the market such as recombinant human clotting factors and plasma concentrated coagulation factor show a large list of problems (i.e. intravenous administration with multiple dosing, generation of antibodies, damage due to delays in treatment, viruses, etc). However, no topical antihemorrhagic
standard drug is available. We are convinced that patients with Defective Coagulation Factors (Hemophilia
, von Willebrand disease, etc) will prefer topical than intravenous administrations. Therefore, growth opportunities for topic hemostatic drugs able to stop bleeding
after moderate and severe injury are provided by a large population of both healthy and patients with a specific defective coagulation factor.
Heparins and cumarinic drugs, the standards of care for thrombosis, has serious side-effects and monitoring is required while newer anti Factor Xa drugs have safety concerns. Our new biological drugs
have validated certain new coagulation pathways and targets for which small molecule therapeutics may offer the best therapeutic solution.